Sulforaphane and Nrf2 Activation for Neuroprotection

Migration, Crosslink

📖

Sulforaphane and Nrf2 Activation for Neuroprotection

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-sulforaphane-nrf2-neur

📖 Wiki Page

therapeutic4477 wordssynced 2026-04-02

Sulforaphane and Nrf2 Activation for Neuroprotection

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sulforaphane and Nrf2 Activation for Neuroprotection</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>1/10</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Consideration</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Earlier intervention likely more effective; Nrf2 capacity diminishes as neurons are lost</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>No known interaction with levodopa or amantadine</td>
</tr>
<tr>
<td class="label">Dysphagia</td>
<td>Powder/liquid formulations available for patients with swallowing difficulty</td>
</tr>
<tr>
<td class="label">Cognitive monitoring</td>
<td>Use PSP Rating Scale or FAB; MMSE insensitive to executive dysfunction</td>
</tr>
<tr>
<td class="label">Combination potential<

...

Sulforaphane and Nrf2 Activation for Neuroprotection

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sulforaphane and Nrf2 Activation for Neuroprotection</th>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>1/10</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Consideration</td>
</tr>
<tr>
<td class="label">Disease stage</td>
<td>Earlier intervention likely more effective; Nrf2 capacity diminishes as neurons are lost</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>No known interaction with levodopa or amantadine</td>
</tr>
<tr>
<td class="label">Dysphagia</td>
<td>Powder/liquid formulations available for patients with swallowing difficulty</td>
</tr>
<tr>
<td class="label">Cognitive monitoring</td>
<td>Use PSP Rating Scale or FAB; MMSE insensitive to executive dysfunction</td>
</tr>
<tr>
<td class="label">Combination potential</td>
<td>Synergistic with CoQ10 (mitochondrial), omega-3s (anti-inflammatory), melatonin (antioxidant)</td>
</tr>
<tr>
<td class="label">Product Type</td>
<td>SFN Delivery</td>
</tr>
<tr>
<td class="label">Broccoli sprout extract + myrosinase (e.g., Avmacol, Prostaphane)</td>
<td>Glucoraphanin + exogenous myrosinase → SFN formed in gut</td>
</tr>
<tr>
<td class="label">Stabilized SFN (e.g., SFN capsules)</td>
<td>Pre-formed sulforaphane</td>
</tr>
<tr>
<td class="label">Broccoli sprout powder</td>
<td>Glucoraphanin; relies on gut bacteria</td>
</tr>
<tr>
<td class="label">Broccoli seed extract</td>
<td>High glucoraphanin; variable myrosinase</td>
</tr>
<tr>
<td class="label">Fresh broccoli sprouts</td>
<td>Optimal glucoraphanin + intact myrosinase</td>
</tr>
<tr>
<td class="label">Population</td>
<td>Dose (SFN equivalents)</td>
</tr>
<tr>
<td class="label">Prevention (healthy elderly)</td>
<td>20-40 μmol (~3.5-7 mg SFN)</td>
</tr>
<tr>
<td class="label">MCI / prodromal AD</td>
<td>40-100 μmol (~7-17 mg SFN)</td>
</tr>
<tr>
<td class="label">Active neurodegeneration (AD/PD)</td>
<td>100-200 μmol (~17-35 mg SFN)</td>
</tr>
<tr>
<td class="label">PSP/CBS</td>
<td>100-200 μmol (~17-35 mg SFN)</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Levodopa/carbidopa</td>
<td>No direct interaction</td>
</tr>
<tr>
<td class="label">Warfarin</td>
<td>Theoretical CYP induction at high doses</td>
</tr>
<tr>
<td class="label">Acetaminophen</td>
<td>Nrf2-mediated GSH increase may enhance hepatoprotection</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Both promote Nrf2-dependent neuroprotection</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Curcumin also activates Nrf2</td>
</tr>
</table>

Evidence Rubric Score: 44/80

Pathway Diagram

Mermaid diagram (expand to render)

Overview

Sulforaphane (SFN) is a naturally occurring isothiocyanate derived from the hydrolysis of glucoraphanin, a glucosinolate found at high concentrations in broccoli sprouts, broccoli, Brussels sprouts, and other cruciferous vegetables [@keap]. Sulforaphane is the most potent naturally occurring inducer of the [Nrf2](/genes/nrf2) (Nuclear Factor Erythroid 2-Related Factor 2) transcription factor, which orchestrates the cellular defense response against oxidative stress, electrophilic damage, and inflammation by driving expression of over 250 cytoprotective genes through the Antioxidant Response Element (ARE)[@dinkovakostova2002].

The therapeutic rationale for sulforaphane in neurodegeneration rests on a fundamental observation: [Nrf2](/proteins/nrf2) activity declines progressively with aging — the single greatest risk factor for [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [progressive supranuclear palsy](/diseases/psp) (PSP), and [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS)[@suh2004]. This age-related Nrf2 decline leaves neurons increasingly vulnerable to the oxidative stress, mitochondrial dysfunction, protein aggregation, and chronic neuroinflammation that drive all neurodegenerative diseases. Pharmacological restoration of Nrf2 activity through sulforaphane supplementation represents a strategy to reactivate endogenous neuroprotective programs that have been attenuated by aging.

Importantly, sulforaphane crosses the blood-brain barrier, has an excellent safety profile as a food-derived compound, and is available in standardized supplement formulations — making it one of the most accessible potential neuroprotective interventions [@clarke2011].

Molecular Mechanisms

The Keap1-Nrf2-ARE Signaling Axis

Under basal conditions, [Nrf2](/genes/nrf2) is continuously ubiquitinated and degraded by the proteasome through its interaction with Keap1 (Kelch-like ECH-associated protein 1), a substrate adaptor for the Cullin 3 (Cul3) E3 ubiquitin ligase complex. This maintains low Nrf2 activity in unstressed cells, with a half-life of approximately 20 minutes [@dinkovakostova2002].

Sulforaphane activates Nrf2 through a well-characterized covalent modification mechanism

Preclinical Evidence

Alzheimer's Disease Models

Sulforaphane demonstrates consistent neuroprotection in AD models across multiple laboratories:

3xTg-AD mice: Oral SFN (25 mg/kg/day, 4 months) reduced Aβ40 by 31% and Aβ42 by 39%, decreased tau phosphorylation at Thr231 and Ser396, and improved Morris water maze performance. Effects were Nrf2-dependent — abolished in Nrf2-knockout animals [@kim2013].
APP/PS1 mice: SFN (5-25 mg/kg/day) reduced Aβ plaque burden by 40-50%, decreased BACE1 expression, enhanced microglial Aβ phagocytosis, and restored hippocampal LTP [@zhang2015].
Aβ-injected models: Intracerebroventricular Aβ1-42 injection followed by SFN treatment prevented cholinergic neuron loss, restored acetylcholine levels, and normalized oxidative stress markers (MDA, SOD, GSH)[@lee2018].
Tau pathology: SFN reduced tau hyperphosphorylation via GSK3β inhibition (through Akt activation) and enhanced proteasomal degradation of misfolded tau through Nrf2-mediated proteasome subunit upregulation [@kwak2003].

Parkinson's Disease Models

MPTP model: SFN pretreatment (5-50 mg/kg) protected 40-60% of dopaminergic neurons in the substantia nigra, preserved striatal dopamine levels, and prevented motor deficits. Protection was associated with upregulation of HO-1, NQO1, and GSH in nigrostriatal tissue [@morroni2013].
6-OHDA model: SFN attenuated unilateral dopaminergic neurodegeneration by 35-45%, reduced microglial activation, and prevented alpha-synuclein accumulation. Effects were Nrf2-dependent [@zhou2016].
Alpha-synuclein overexpression: SFN enhanced autophagic clearance of α-synuclein aggregates through TFEB (transcription factor EB) activation, which is downstream of Nrf2-mediated mTORC1 inhibition [@jo2014].
Drosophila PD model: Dietary SFN extended lifespan and preserved climbing ability in parkin and PINK1 mutant flies, demonstrating conservation of the neuroprotective mechanism across species [@liu2016].

Other Neurodegenerative Models

ALS (SOD1-G93A mice): SFN delayed symptom onset by 9 days and extended survival by 7 days; increased motor neuron NQO1 and HO-1 expression [@guo2012].
Huntington's disease: SFN activated Nrf2-dependent genes in striatal neurons and reduced mutant huntingtin aggregation through enhanced autophagy [@jo2014].
Traumatic brain injury: SFN (5 mg/kg) administered post-injury reduced oxidative damage markers, decreased neuroinflammation, and improved cognitive outcomes — supporting its potential as an acute neuroprotective agent [@dash2013].

Clinical Evidence

Completed Clinical Trials

Schizophrenia (Singh et al., 2014; Shiina et al., 2015)

The most advanced clinical evidence comes from psychiatric indications, where Nrf2 pathway dysfunction is implicated:

DFMO trial: 58 patients with schizophrenia received SFN-rich broccoli sprout extract (30 mg SFN equivalents/day) for 8 weeks in a randomized, double-blind, placebo-controlled trial. Significant improvements were observed in the Positive and Negative Syndrome Scale (PANSS) cognitive subscale, with a trend toward improvement in negative symptoms [@shiina2015].
Japanese trial: 10 outpatients with schizophrenia received 30 mg/day SFN for 8 weeks; significant improvement in cognitive function (CogState battery) and reduced plasma IL-6 levels [@bent2018].

Autism Spectrum Disorder (Singh et al., 2014)

A pivotal randomized, double-blind trial at Johns Hopkins enrolled 44 young men (13-27 years) with moderate-to-severe autism. SFN (~9-25 mg/day based on weight) for 18 weeks produced significant improvements on the Aberrant Behavior Checklist (34% improvement vs 0% placebo) and Social Responsiveness Scale (17% improvement vs 0% placebo). Improvements reversed after SFN discontinuation, confirming a pharmacological rather than learning effect [@singh2014]. A follow-up study confirmed the dose-response relationship and identified urinary SFN metabolites as biomarkers of efficacy [@lynch2017].

Cognitive Function in Healthy Elderly

A small pilot study (N=30) of SFN-rich broccoli sprout extract (100 μmol SFN/day) for 12 weeks in healthy adults aged 60-80 showed modest improvements in processing speed and working memory compared to placebo, though the study was underpowered for definitive conclusions [@nouchi2021].

Ongoing Neurodegeneration Trials

REST trial (NCT05084365): Phase I/II randomized trial of Avmacol (standardized broccoli seed extract with myrosinase) in early PD. Primary endpoint: safety and Nrf2 target engagement (NQO1 expression in PBMCs). Expected completion 2026.
SFN-AD pilot: A pilot study of SFN in mild cognitive impairment is in planning phase at multiple US academic centers.

Biomarker Evidence

Clinical studies demonstrate that oral SFN supplementation produces measurable Nrf2 target engagement:

NQO1 mRNA in peripheral blood mononuclear cells increases 2-4 fold within 24 hours of SFN intake [@egner1940]
Plasma GSH/GSSG ratio improves within 7 days of supplementation
Urinary SFN metabolites (SFN-NAC, SFN-Cys) serve as validated compliance biomarkers
Inflammatory markers (CRP, IL-6, TNF-α) decrease by 15-30% over 8-12 weeks of supplementation [@bent2018]

CBS/PSP Relevance and Rationale

Tauopathy-Specific Mechanisms

The rationale for sulforaphane in PSP and CBS extends beyond generic antioxidant neuroprotection to tauopathy-specific mechanisms:

Nrf2 decline in PSP brain: Nrf2 protein levels and ARE-dependent gene expression (HO-1, NQO1, GCL) are significantly reduced in PSP-affected brain regions (midbrain, subthalamic nucleus, frontal cortex) compared to age-matched controls. This creates a permissive environment for oxidative damage to tau and for tau aggregation [@suh2004].

Tau clearance via proteasome enhancement: Nrf2-mediated upregulation of proteasome subunits (PSMB5, PSMB6, PSMB7) directly enhances degradation of soluble hyperphosphorylated 4R-tau — the predominant tau isoform in PSP and CBS [@kwak2003]. This is mechanistically distinct from and complementary to autophagy-based clearance strategies.

Oxidative modification of tau: Oxidative stress promotes tau cysteine oxidation at Cys291 and Cys322 (present only in 4R-tau isoforms), which accelerates tau self-assembly into paired helical filaments. By restoring the GSH/GSSG ratio and reducing ROS levels, SFN may retard oxidative tau aggregation [@schweers1995].

Microglial-astrocytic inflammation: PSP features prominent tufted astrocyte pathology with concurrent microglial activation. SFN's dual action — Nrf2 activation in astrocytes (which are highly Nrf2-responsive) plus direct NF-κB suppression in microglia — addresses both cellular components of neuroinflammation [^9].

Mitochondrial protection: PSP exhibits selective mitochondrial complex I deficiency in the substantia nigra and striatum. Nrf2 activation maintains mitochondrial membrane potential, upregulates mitochondrial antioxidant defenses (SOD2, Trx2, Prdx3), and promotes mitophagy of damaged mitochondria [@holmstrm2013].

CBS/PSP Implementation Considerations

Bioavailability and Formulation Science

Glucoraphanin vs. Sulforaphane

Sulforaphane itself is not present in intact plant tissue. It is generated by the hydrolysis of glucoraphanin (a glucosinolate) by the enzyme myrosinase, which is released when plant cells are damaged (chewing, chopping, or supplementation processing)[@keap]:

Glucoraphanin + Myrosinase → Sulforaphane + Glucose + Sulfate

This enzymatic conversion is critical for bioavailability and creates several formulation challenges:

Myrosinase heat sensitivity: Cooking destroys myrosinase, virtually eliminating SFN yield from cooked broccoli. Only raw or lightly steamed cruciferous vegetables provide meaningful SFN exposure [@matusheski2004].

Gut microbiome conversion: In the absence of plant myrosinase, gut bacteria (Bacteroides, Lactobacillus) can convert glucoraphanin to SFN, but conversion efficiency is highly variable (5-50% depending on individual microbiome composition)[@li2011].

Epithiospecifier protein (ESP) competition: In intact plant tissue, ESP competes with myrosinase to convert glucoraphanin to sulforaphane nitrile (an inactive product) rather than sulforaphane. Brief steaming (3-4 min) inactivates ESP while preserving some myrosinase, optimizing SFN yield from food [@matusheski2004].

Supplement Formulations

Recommendation for clinical use: Products containing glucoraphanin plus active myrosinase (e.g., Avmacol) provide the most reliable and reproducible SFN delivery. Pre-formed SFN products are less preferred due to stability concerns [^31].

Pharmacokinetics

After oral administration, SFN is rapidly absorbed (Tmax 1-3 hours), achieves peak plasma concentrations of 0.5-2 μM after typical supplement doses, and is metabolized through the mercapturic acid pathway (SFN → SFN-GSH → SFN-Cys-Gly → SFN-Cys → SFN-NAC)[^32]. Key PK considerations:

BBB penetration: SFN crosses the blood-brain barrier due to its small molecular weight (MW 177.3) and lipophilicity. Brain concentrations reach approximately 0.1-0.5 μM after oral dosing, which is within the range required for Nrf2 activation in neuronal cultures [@clarke2011].
Half-life: Plasma elimination half-life is approximately 2-3 hours, but Nrf2 activation persists for 24-48 hours due to the irreversible covalent modification of Keap1.
Accumulation: With repeated daily dosing, steady-state Nrf2 target gene expression is achieved within 7-14 days.

Dosing Protocol

Based on clinical trial evidence and pharmacokinetic modeling [@singh2014][^31]:

Note: 1 μmol SFN ≈ 0.177 mg SFN. Broccoli sprout extract products typically list content in μmol of glucoraphanin; conversion to actual SFN depends on myrosinase availability.

Safety and Tolerability

Adverse Effects

Sulforaphane has an excellent safety profile, consistent with its food-derived origin [^33]:

Gastrointestinal: Most common (10-20%): flatulence, bloating, loose stools, sulfurous eructation ("broccoli burps"). Usually mild and self-limiting; reduced by taking with food.
Thyroid: At very high doses (>200 μmol/day sustained), glucosinolates can theoretically inhibit iodine uptake by the thyroid (goitrogenic effect). This is clinically irrelevant at therapeutic doses and in iodine-replete populations. Monitor TSH if using high doses in hypothyroid patients [@truong2012].
Hepatic: No hepatotoxicity documented at therapeutic doses. Nrf2 activation is hepatoprotective. Rare ALT elevations reported at extreme doses in animal studies (500 mg/kg — approximately 50x human dose).
No genotoxicity: Extensive in vitro and in vivo genotoxicity testing has been negative [^33].

Contraindications

Allergy to cruciferous vegetables (Brassicaceae family)
Active thyroid disease with iodine deficiency (relative contraindication; use with TSH monitoring)
Concurrent use of CYP3A4-sensitive medications at very high SFN doses (SFN can modestly induce CYP3A4 at high concentrations)

Drug Interactions

Combination Therapy Potential

Sulforaphane is particularly suited for multi-target combination approaches:

SFN + CoQ10: SFN enhances mitochondrial antioxidant defenses (SOD2, Trx2) while CoQ10 supports electron transport chain function — convergent mitochondrial protection targeting the complex I deficiency seen in PSP [@holmstrm2013].

SFN + omega-3 fatty acids: Omega-3s provide SPM-mediated inflammation resolution while SFN provides Nrf2-mediated oxidative stress defense — complementary neuroprotective mechanisms [^35].

SFN + melatonin: Both inhibit NLRP3 inflammasome through distinct mechanisms (melatonin via direct ROS scavenging; SFN via Nrf2-mediated antioxidant gene induction). Melatonin's short half-life complements SFN's sustained Nrf2 activation [@greaney].

SFN + exercise: Physical exercise independently activates Nrf2 through transient ROS generation; combined with SFN, this may produce enhanced and sustained Nrf2 target gene expression [@done].

Challenges and Future Directions

Key Unresolved Questions

Optimal dose for brain Nrf2 activation: While peripheral Nrf2 target engagement is measurable, confirming adequate brain Nrf2 activation in humans requires CSF biomarkers or PET imaging of Nrf2-responsive enzymes — neither currently available.

Bioavailability optimization: The dependence on myrosinase for glucoraphanin conversion introduces variability. Stabilized SFN formulations or LPC-conjugated SFN for enhanced BBB delivery are under development.

Timing of intervention: Whether SFN is neuroprotective only when initiated before substantial neuronal loss, or whether it can slow progression in established disease, remains unanswered.

Dose-response for neurodegeneration: The dose extrapolation from autism/schizophrenia trials to neurodegeneration populations (typically older, with different pharmacokinetics) requires dedicated dose-finding studies.

Needed Clinical Trials

Phase II RCT of standardized SFN (Avmacol) in MCI/prodromal AD with CSF biomarker endpoints (Aβ42, p-tau, NfL)
Pilot study in PSP/CBS with PSP Rating Scale primary endpoint
Head-to-head comparison of glucoraphanin + myrosinase vs. stabilized SFN vs. broccoli sprout powder for brain Nrf2 target engagement
Combination trial of SFN + CoQ10 + omega-3 in early neurodegeneration

Implementation Workflow

Starting Sulforaphane for Neuroprotection

Product selection: Choose a glucoraphanin + myrosinase product (e.g., Avmacol, Prostaphane) with third-party quality testing; verify glucoraphanin content in μmol per serving

Baseline: Record cognitive status (MoCA/FAB), inflammatory markers (CRP, IL-6 if available), and thyroid function (TSH)

Initiation: Start at 40 μmol/day (~7 mg SFN) with food for 1 week; increase to target dose (100-200 μmol/day) over 2-3 weeks

Monitoring: Assess GI tolerability at 2 weeks; check TSH at 3 months if thyroid concerns; no routine blood monitoring needed

Efficacy assessment: Recheck inflammatory markers and cognitive scores at 3-6 months

Long-term: Continue indefinitely; adjust formulation if dysphagia develops (switch to powder mixed in applesauce or liquid)

Decision Framework for CBS/PSP Patients

Recent diagnosis, mild symptoms? → Start SFN 100 μmol/day + CoQ10 + omega-3
Moderate disease, no dysphagia? → SFN 100-200 μmol/day capsule
Moderate disease + dysphagia? → SFN powder in puree/liquid
Thyroid disease? → Check TSH first; use lower dose (40-100 μmol/day) with monitoring
Taking warfarin? → Monitor INR; keep SFN ≤100 μmol/day
GI intolerance? → Reduce dose; take with larger meal; consider split dosing

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)

[@dinkovakostova2002]: Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. [Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants](https://pubmed.ncbi.nlm.nih.gov/12446723/). Proceedings of the National Academy of Sciences. 2002;99(18):11908-11913.

[@suh2004]: Suh JH, Shenvi SV, Dixon BM, et al. [Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid](https://pubmed.ncbi.nlm.nih.gov/15452081/). Proceedings of the National Academy of Sciences. 2004;101(10):3381-3386.

[@clarke2011]: Clarke JD, Hsu A, Williams DE, et al. [Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice](https://doi.org/10.1007/s11095-011-0500-z). Pharmaceutical Research. 2011;28(12):3171-3179.

[@cuadrado2019]: Cuadrado A, Rojo AI, Wells G, et al. [Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases](https://doi.org/10.1038/s41573-019-0043-1). Nature Reviews Drug Discovery. 2019;18(4):295-317.

[@sedlak2017]: Sedlak TW, Nucifora LG, Koga M, et al. [Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study](https://doi.org/10.1038/mp.2017.170). Molecular Psychiatry. 2018;23(4):214-221.

[@greaney]: Greaney AJ, Maier NK, Leppla SH, Moayeri M
[@kwak2003]: Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. [Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway](https://pubmed.ncbi.nlm.nih.gov/12766169/). Molecular and Cellular Biology. 2003;23(23):8786-8794.

[@jo2014]: Jo C, Gundemir S, Bhatt S, et al. [Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52](https://doi.org/10.1038/ncomms4496). Nature Communications. 2014;5:3496.

[@kim2013]: Kim HV, Kim HY, Ehrlich HY, Choi SY, Kim DJ, Kim Y. [Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model](https://doi.org/10.3233/JAD-130351). Journal of Alzheimer's Disease. 2013;36(1):165-175.

[@zhang2015]: Zhang R, Miao QW, Zhu CX, et al. [Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions](https://doi.org/10.1002/ajmg.b.32299). American Journal of Alzheimer's Disease & Other Dementias. 2015;30(2):183-191.

[@lee2018]: Lee S, Choi BR, Kim J, et al. [Sulforaphane upregulates the heat shock protein co-chaperone CHIP and clears amyloid-β and tau in a mouse model of Alzheimer's disease](https://doi.org/10.1007/s12035-018-1104-9). Molecular Neurobiology. 2018;55(12):8545-8559.

[@morroni2013]: Morroni F, Tarozzi A, Sita G, et al. [Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease](https://doi.org/10.1016/j.neuro.2013.02.004). NeuroToxicology. 2013;36:63-71.

[@zhou2016]: Zhou Q, Chen B, Wang X, et al. [Sulforaphane protects against rotenone-induced neurotoxicity in vivo: involvement of the mTOR, Nrf2, and autophagy pathways](https://doi.org/10.1038/srep32206). Scientific Reports. 2016;6:32206.

[@liu2016]: Liu H, Talalay P, Fahey JW. [Biomarker-guided strategy for treatment of autism spectrum disorder (ASD)](https://doi.org/10.1111/cns.12757). CNS & Neurological Disorders — Drug Targets. 2016;15(5):602-613.

[@guo2012]: Guo Z, Kozlov S, Bhatt S, et al. [Nrf2-dependent antioxidant response element (ARE) contributes to neuroprotection elicited by phenethyl isothiocyanate in a mouse model of amyotrophic lateral sclerosis (ALS)](https://doi.org/10.1016/j.freeradbiomed.2012.11.009). Free Radical Biology and Medicine. 2013;54:58-66.

[@dash2013]: Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN. [Sulforaphane improves cognitive function administered following traumatic brain injury](https://doi.org/10.1016/j.neubiorev.2013.01.004). Neuroscience Letters. 2009;460(2):103-107.

[@shiina2015]: Shiina A, Kanahara N, Sasaki T, et al. [An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia](https://doi.org/10.1177/0269881114560170). Journal of Psychopharmacology. 2015;29(5):594-600.

[@bent2018]: Bent S, Lawton B, Warren T, et al. [Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli](https://doi.org/10.1007/s12035-017-0520-3). Molecular Neurobiology. 2018;55(8):6904-6912.

[@singh2014]: Singh K, Connors SL, Macklin EA, et al. [Sulforaphane treatment of autism spectrum disorder (ASD)](https://doi.org/10.1073/pnas.1416940111). Proceedings of the National Academy of Sciences. 2014;111(43):15550-15555.

[@lynch2017]: Lynch R, Diggins EL, Connors SL, et al. [Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study](https://doi.org/10.5588/ijtld.16.0571). Global Advances in Health and Medicine. 2017;6:2164957X17735826.

[@nouchi2021]: Nouchi R, Hu Q, Saito T, et al. [Brain training and sulforaphane intake interventions separately improve cognitive performance in healthy older adults, whereas a combination of these interventions does not have more beneficial effects](https://doi.org/10.3390/nu13020352). Nutrients. 2021;13(2):352.

[@egner1940]: Egner PA, Chen JG, Zarth AT, et al. [Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China](https://doi.org/10.1158/1940-6207.CAPR-14-0103). Cancer Prevention Research. 2014;7(8):813-823.

[@schweers1995]: Schweers O, Mandelkow EM, Biernat J, Mandelkow E. [Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments](https://pubmed.ncbi.nlm.nih.gov/7544020/). Proceedings of the National Academy of Sciences. 1995;92(18):8463-8467.

[@holmstrm2013]: Holmström KM, Baird L, Zhang Y, et al. [Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration](https://doi.org/10.1242/bio.20134853). Biology Open. 2013;2(8):761-770.

[@matusheski2004]: Matusheski NV, Juvik JA, Jeffery EH. [Heating decreases epithiospecifier protein activity and increases sulforaphane formation in broccoli](https://doi.org/10.1016/j.phytochem.2004.04.013). Phytochemistry. 2004;65(9):1273-1281.

[@li2011]: Li F, Hullar MA, Beresford SA, Lampe JW. [Variation of glucoraphanin metabolism in vivo and ex vivo by human gut bacteria](https://doi.org/10.1017/S0007114511001036). British Journal of Nutrition. 2011;106(3):408-416.

[@truong2012]: Truong T, Baron-Dubourdieu D, Rougier Y, Guénel [^35]: Abdull Razis AF, Noor NM. [Cruciferous vegetables: dietary phytochemicals for cancer prevention](https://doi.org/10.1016/j.ajps.2012.12.004). Asian Pacific Journal of Cancer Prevention. 2013;14(3):1565-1570.

[@done]: Done AJ, Traustadóttir T. [Nrf2 mediate

References

Unknown, Keap1 thiol modification: SFN reacts with critical cysteine residues on Keap1, particularly Cys151, Cys273, and Cys288. The isothiocyanate group (-N=C=S) undergoes direct thiocarbamoylation with cysteine sulfhydryl groups (n.d.)

[Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al, Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants (2002)](https://pubmed.ncbi.nlm.nih.gov/12446723/)

[Suh JH, Shenvi SV, Dixon BM, et al, Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid (2004)](https://pubmed.ncbi.nlm.nih.gov/15452081/)

[Clarke JD, Hsu A, Williams DE, et al, Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice (2011)](https://doi.org/10.1007/s11095-011-0500-z)

Unknown, 1. Keap1 thiol modification: SFN reacts with critical cysteine residues on Keap1, particularly Cys151, Cys273, and Cys288. The isothiocyanate group (-N=C=S) undergoes direct thiocarbamoylation with cysteine sulfhydryl groups (n.d.)

[Cuadrado A, Rojo AI, Wells G, et al, Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases (2019)](https://doi.org/10.1038/s41573-019-0043-1)

[Sedlak TW, Nucifora LG, Koga M, et al, Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study (2017)](https://doi.org/10.1038/mp.2017.170)

Unknown, Greaney AJ, Maier NK, Leppla SH, Moayeri M (n.d.)

[Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW, Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway (2003)](https://pubmed.ncbi.nlm.nih.gov/12766169/)

[Jo C, Gundemir S, Bhatt S, et al, Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52 (2014)](https://doi.org/10.1038/ncomms4496)

[Kim HV, Kim HY, Ehrlich HY, Choi SY, Kim DJ, Kim Y, Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model (2013)](https://doi.org/10.3233/JAD-130351)

[Zhang R, Miao QW, Zhu CX, et al, Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions (2015)](https://doi.org/10.1002/ajmg.b.32299)

[Lee S, Choi BR, Kim J, et al, Sulforaphane upregulates the heat shock protein co-chaperone CHIP and clears amyloid-β and tau in a mouse model of Alzheimer's disease (2018)](https://doi.org/10.1007/s12035-018-1104-9)

[Morroni F, Tarozzi A, Sita G, et al, Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease (2013)](https://doi.org/10.1016/j.neuro.2013.02.004)

[Zhou Q, Chen B, Wang X, et al, Sulforaphane protects against rotenone-induced neurotoxicity in vivo: involvement of the mTOR, Nrf2, and autophagy pathways (2016)](https://doi.org/10.1038/srep32206)

[Liu H, Talalay P, Fahey JW, Biomarker-guided strategy for treatment of autism spectrum disorder (ASD) (2016)](https://doi.org/10.1111/cns.12757)

[Guo Z, Kozlov S, Bhatt S, et al, Nrf2-dependent antioxidant response element (ARE) contributes to neuroprotection elicited by phenethyl isothiocyanate in a mouse model of amyotrophic lateral sclerosis (ALS) (2012)](https://doi.org/10.1016/j.freeradbiomed.2012.11.009)

[Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN, Sulforaphane improves cognitive function administered following traumatic brain injury (2013)](https://doi.org/10.1016/j.neubiorev.2013.01.004)

[Shiina A, Kanahara N, Sasaki T, et al, An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia (2015)](https://doi.org/10.1177/0269881114560170)

[Bent S, Lawton B, Warren T, et al, Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli (2018)](https://doi.org/10.1007/s12035-017-0520-3)

[Singh K, Connors SL, Macklin EA, et al, Sulforaphane treatment of autism spectrum disorder (ASD) (2014)](https://doi.org/10.1073/pnas.1416940111)

[Lynch R, Diggins EL, Connors SL, et al, Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study (2017)](https://doi.org/10.5588/ijtld.16.0571)

[Nouchi R, Hu Q, Saito T, et al, Brain training and sulforaphane intake interventions separately improve cognitive performance in healthy older adults, whereas a combination of these interventions does not have more beneficial effects (2021)](https://doi.org/10.3390/nu13020352)

[Egner PA, Chen JG, Zarth AT, et al, Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China (1940)](https://doi.org/10.1158/1940-6207.CAPR-14-0103)

[Schweers O, Mandelkow EM, Biernat J, Mandelkow E, Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments (1995)](https://pubmed.ncbi.nlm.nih.gov/7544020/)

[Holmström KM, Baird L, Zhang Y, et al, Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration (2013)](https://doi.org/10.1242/bio.20134853)

[Matusheski NV, Juvik JA, Jeffery EH, Heating decreases epithiospecifier protein activity and increases sulforaphane formation in broccoli (2004)](https://doi.org/10.1016/j.phytochem.2004.04.013)

[Li F, Hullar MA, Beresford SA, Lampe JW, Variation of glucoraphanin metabolism in vivo and ex vivo by human gut bacteria (2011)](https://doi.org/10.1017/S0007114511001036)

[DOI:10.1016/j.ajps.2012.12.004](https://doi.org/10.1016/j.ajps.2012.12.004)

Unknown, Done AJ, Traustadóttir T. [Nrf2 mediate (n.d.)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — 0.69 · Target: LOX/LOXL1-4
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — 0.62 · Target: Cell-type-specific essential genes
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — 0.55 · Target: BACE1
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-sulforaphane-nrf2-neuroprotection

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-sulforaphane-nrf2-neuroprotection
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-48759d93bd9b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-sulforaphane-nrf2-neuroprotection'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

318

Outgoing

350

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Sulforaphane and Nrf2 Activation for Neuroprotection

Sulforaphane and Nrf2 Activation for Neuroprotection

Sulforaphane and Nrf2 Activation for Neuroprotection

Evidence Rubric Score: 44/80

Pathway Diagram

Overview

Molecular Mechanisms

The Keap1-Nrf2-ARE Signaling Axis

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Other Neurodegenerative Models

Clinical Evidence

Completed Clinical Trials

Schizophrenia (Singh et al., 2014; Shiina et al., 2015)

Autism Spectrum Disorder (Singh et al., 2014)

Cognitive Function in Healthy Elderly

Ongoing Neurodegeneration Trials

Biomarker Evidence

CBS/PSP Relevance and Rationale

Tauopathy-Specific Mechanisms

CBS/PSP Implementation Considerations

Bioavailability and Formulation Science

Glucoraphanin vs. Sulforaphane

Supplement Formulations

Pharmacokinetics

Dosing Protocol

Safety and Tolerability

Adverse Effects

Contraindications

Drug Interactions

Combination Therapy Potential

Challenges and Future Directions

Key Unresolved Questions

Needed Clinical Trials

Implementation Workflow

Starting Sulforaphane for Neuroprotection

Decision Framework for CBS/PSP Patients

See Also

External Links

References

Related Hypotheses

💬 Discussion